… with small cell lung cancer (SCLC) are frequently denied surgical treatment despite growing
… intervention is integrated in a tri-modality therapy concept including chemotherapy, surgery, …

This study is to evaluate and report the prognostic factors of N2 positive stage IIIA non-small
cell lung cancer (NSCLC) treated with concurrent radiochemotherapy (CRCT) and surgery. …

This review addresses recent evidence on the role of surgery in different clinical subsets of
so called 'potentially resectable' stage III NSCLC. In some selected subsets of stage III …

… The treatment of stage III non–small-cell lung cancer has evolved over the last two decades,
with combined-modality therapy the current standard of care. As a result, intermediate and …

… A German Multicentre trial (Minister Group) is testing the optimal timing of radiation therapy
within a trimodality protocol in inoperable stages IHA and ULB, given preoperatively in one …

… Pathologic stage IIIA non-small cell lung cancer (NSCLC) is a challenging disease to treat
and the role of postoperative radiotherapy (PORT) in patients following resection remains …

… Finally, 303 patients who underwent tri-modality therapy were included in this study (Figure
1). Our institutional review board approved this retrospective cohort study (#2022-01-086), …

… Induction treatment comprised 45 Gy RT delivered to primary tumor and pathologic hilar
and/or mediastinal nodes on CT-can (CTV) with an extra-margin of 1 to 1.5 cm (PTV). A 5-field …

… ) and clinical outcome following tri-modality therapy in patients with … 46 patients who received
tri-modality therapy between 1997 and … non small cell lung cancer. J Thor Oncol 4:729–801 …

… Combined Modality Therapy in NSCLC I, Mon, 13:45 - 15:30 Concomitant radio-chemotherapy
(RT-CT) versus sequential RT-CT in locally advanced non-small cell lung cancer (NSCLC…